The OHIO Department, headed by Estelle Duprez and Raynier Devillier, comprises six teams focusing on hematology, immunology and innovative therapies.
With around 100 members, OHIO explores tumor mechanisms linked to the microenvironment and cellular heterogeneity, with the aim of overcoming treatment resistance.

In collaboration with the IPC, the department is developing a bidirectional "bench to bedside" approach, combining stem cell biology, immunotherapy and epigenetics. An important focus is acute myeloid leukemia (AML), where advanced technologies such as mass cytometry and single-cell analysis are identifying biomarkers and new therapies.

Treatments that reactivateNK cells are being studied. Thanks to a culture of collaboration between clinicians and researchers, OHIO enhances the visibility of its work and inspires clinical practice, while promoting interdisciplinary projects and scientific communication via the OHIOLetter.